進階搜尋


  查詢北醫館藏
系統識別號 U0007-2807201116265000
論文名稱(中文) 利用控釋型膜衣製備多單元顆粒之脈衝式藥物傳輸系統探討
論文名稱(英文) Evaluation of controlled release membrane in multiparticulate pulsatile drug delivery system
校院名稱 臺北醫學大學
系所名稱(中) 藥學研究所
系所名稱(英) Graduate Institute of Pharmacy
學年度 99
學期 2
出版年 100
研究生(中文) 林成懋
研究生(英文) Cheng-Mao Lin
電子信箱 m301098036@tmu.edu.tw
學號 M301098036
學位類別 碩士
語文別 中文
口試日期 2011-07-19
論文頁數 102頁
口試委員 委員-蔡義弘
委員-林山陽
委員-林文貞
委員-何秀娥
指導教授-許明照
中文關鍵字 控釋型膜衣  多單元顆粒  脈衝式  藥物傳輸系統 
英文關鍵字 controlled release  membrane  multiparticulate  pulsatile  drug delivery system 
學科別分類
中文摘要 控釋劑型 (controlled release dosage form)的發展延長了藥效持續時間,進而使疾病治療的效果有所提升,而隨著更多節律性相關疾病的發現,在其容易發作的時段給予足夠的藥物濃度勢必能夠帶來更精確、有效的治療效果,因此利用脈衝式藥物傳輸系統 (pulsatile drug delivery system)來達到節律性治療 (chronotherapy)的給藥方式便被發展出來。
利用一般錠片來達到脈衝式給藥的方法為近期常被探討的題材,
但如以多單元顆粒 (multiparticulate)劑型來達到脈衝式藥物控釋效果而言,確實是較少見的;因此本研究主要探討不同含量的滲透壓物質(NaCl)之多單元顆粒劑型,改變其外層膜衣 (Eudragit® RS 30D)厚度、塑化劑 (TEC)添加量,並觀察對藥物釋放造成的影響,最後利用體外溶離試驗及掃描式電子顯微鏡探討此多單元顆粒之脈衝式藥物釋放機轉。
首先,在模式藥物選擇上為皆具有節律性治療意義之降血壓藥物
propranolol HCl以及胃酸抑制劑omeprazole basic、omeprazole sodium,利用擠壓搓圓法各製備出含4%、20% NaCl 的滲透壓物質核心圓粒(core),且包覆上添加含量為TEC 15%、20%之四種膜衣厚度 (10、 20、30、40%)的Eudragit® RS 30D 膜衣,藉由體外溶離試驗,可以觀察出不同滲透壓物質添加量及膜衣含量比率對藥物釋放造成的影響,並利用掃描式電子顯微鏡觀察出因核心圓粒滲透壓而造成膜衣破裂之情形。
研究結果可因三種不同特性之模式藥物而分為三種趨勢,以藥物延遲釋放時間及藥物釋放速率做為脈衝式給藥的判斷基準而言,達到脈衝式藥物釋放趨勢之顯著性為:propranolol HCl > omeprazole sodium >omeprazole basic。由上述結果可以得到兩個結論,第一、利用滲透壓系統 (NaCl)配合控釋型膜衣 (Eudragit® RS 30D)是為製備多單元顆粒脈衝劑型之可行處方設計;第二、因Eudragit® RS 30D 膜衣上含有3%且帶正電之四級銨基基團,藥物釋放量即會隨著模式藥物特性的不同而改變,其中帶負電、低溶解度的omeprazole basic 會和膜衣上帶正電性的銨基產生離子交換作用而導致釋放量降低,而帶負電、高溶解度的omeprazolesodium 則為次之,最後則是帶正電、高溶解度且不與膜衣產生作用的propranolol HCl 會有最佳的藥物釋放效果;第三、在以上述膜衣處方設計的前提下,利用三種不同特性模式藥物之比較結果,其可做為以控釋型膜衣製備多單元顆粒脈衝式劑型之篩選帄台。
英文摘要 The development of controlled-release drug delivery system bringsbenefits to the treatment of diseases by prolong the duration of drug release. As the discovery of diseases with circadian rhythms, it will be more accuracy and efficiency in the treatment of such diseases when the
drug is released at special time point. Therefore the concept of pulsatile drug delivery system is studied to achieve the goal of chronotherapy.
It is frequently-discussed in the usage of a tablet to achieve pulsatile drug delivery system compared to the usage of the multiparticulate in recent years. The purpose of this research is to compare the drug release in
different amount of osmogent inside the multiparticulate core which is coated by polymer membrane with various coating level and amount of plastizer. The mechanism of drug release is also evaluated by using the scanning electron microscopy and the dissolution test.
At first, an anti-hypertension dug: propranolol HCl, two anti-acid secretion drugs with different salt forms: omeprazole basic and omeprazole sodium were chosen as model drugs. Each types of model drugs contained 4% or 20% of osmogent (NaCl) was formulated by extrusion-spheronization, and coated by Eudragit® RS 30D membrane with 15%, 20% of triethylcitrate as plasticizer at 10, 20, 30, 40% coating
level. Finally, it is obvious to distinguish three different types of release patterns based on the different characteristics of model drugs by the resultof dissolution test in pH 6.8 medium and SEM. The pulsatile drug release
pattern was achieved as the order of propranolol HCl > omeprazole sodium > omeprazole basic, based on the judgment of lag-time and drug release rate after a lag-time period.
In conclusion, it is an applicable formulation design to combine osmotic system (NaCl) with controlled released membrane (Eudragit® RS30D) in multiparticulate pulsatile drug delivery dosage form activated by membrane rupture. Second, it is possible that there is an ion-ion
interaction between Eudragit® RS 30D polymer which possess an quaternary ammonium group with positive charge. With different characteristics of : omeprazole basic, which possess negative charge and slightly soluble solubility. Omeprazole sodium, which possess negative charge and freely soluble solubility. Propranolol HCl, which possess
positive charge and freely soluble solubility.
Consequently, the order of pulsatile drug release pattern is: propranolol HCl > omeprazole sodium >
omeprazole basic. Finally, it can be a preliminary screening tool to estimate the pulsatile drug release pattern according to the comparison of three different types of model drugs based on this formulation design.
論文目次 目錄
目錄 .............................................. I
附圖目錄 .......................................... III
附表目錄 .......................................... IX
中文摘要 .......................................... XI
Abstract .......................................... XIII
第壹章 緒論 ........................................1
第一節 研究背景 .................................................1
一、節律型疾病介紹 (Diseases with established circadian ....
rhythms) ...........................................1
二、多單元顆粒脈衝式藥物傳遞系統簡介 (Multiparticulate
pulsatile drug delivery system)[11] .............................................. 10
三、模式藥物簡介 (Model drug):Omeprazole ......... 27
第二節 研究動機 ................................................ 32
第貳章 實驗方法與研究材料 ................................................ 33
第一節 實驗材料及儀器設備 ................................................ 33
一、 實驗材料 ................................................ 33
二、 儀器設備 ................................................ 34
第二節 實驗方法 ................................................ 35
一、 劑型的設計與製備 ................................................ 35
二、 體外溶離試驗 ................................................ 48
三、 膜衣拉張力試驗 ................................................ 48
四、 溶解度試驗 ................................................ 50
五、 藥物吸附試驗 ................................................ 51
六、 掃描式電子顯微鏡試驗 ................................................ 51
七、 分析方法 ................................................ 52
八、 數據統計分析 ................................................ 52
第參章 結果與討論 ................................................ 54
第一節 分析方法之確立 ................................................ 54
第二節 體外溶離試驗 ................................................ 61
第三節 膜衣拉張力試驗 ................................................ 81
第四節 藥物吸附試驗 ................................................ 82
第五節 溶解度試驗 ................................................ 84
第六節 掃描式電子顯微鏡試驗 ................................................ 88
第肆章 結論 ....................................... 97
第伍章 參考資料 ................................................ 99
參考文獻 1. Lévi, F. Circadian chronotherapy for human cancers. Lancet
Oncology 2, 307-315 (2001).
2. Lemmer, B. Chronobiology, drug-delivery, and chronotherapeutics.
Advanced Drug Delivery Reviews 59, 825-827 (2007).
3. Smolensky, M.H., Lemmer, B. & Reinberg, A.E. Chronobiology
and chronotherapy of allergic rhinitis and bronchial asthma.
Advanced Drug Delivery Reviews 59, 852-882 (2007).
4. Reinberg, A., et al. Circadian and circannual rhythms of allergic
rhinitis: An epidemiologic study involving chronobiologic methods.
Journal of Allergy and Clinical Immunology 81, 51-62 (1988).
5. SAKULA, A. Sir John Floyer' s A Treatise of the Asthma (1698).
Thorax 39, 248-254 (1984).
6. Smolensky, M.H., Tatar, S.E. & Bergman, S.A. Circadian rhythmic
aspects of human cardiovascular function: a review by
chronobiologic statistical methods. Chronobiologia 3, 337-371
(1976).
7. Kario, K. & Shimada, K. Risers and Extreme-Dippers of Nocturnal
Blood Pressure in Hypertension: Antihypertensive Strategy for
Nocturnal Blood Pressure. Clinical and Experimental Hypertension
26, 177-189 (2004).
8. Lemmer, B. The importance of circadian rhythms on drug response
in hypertension and coronary heart disease-from mice and man.
Pharmacology and Therapeutics 111, 629-651 (2006).
9. Khan, Z., Pillay, V., Choonara, Y.E. & Du Toit, L.C. Drug delivery
technologies for chronotherapeutic applications Drug delivery
technologies for chronotherapeutic applications. Pharmaceutical
Development and Technology 14, 602-612 (2009).
10. Sugimoto, M., et al. Different dosage regimens of rabeprazole for
nocturnal gastric acid inhibition in relation to cytochrome P450
2C19 genotype status. Clinical Pharmacology and Therapeutics 76,
290-301 (2004).
11. Roy, P. & Shahiwala, A. Multiparticulate formulation approach topulsatile drug delivery: Current perspectives. Journal of Controlled
Release 134, 74-80 (2009).
12. Ueda, Y., Hata, T., Yamaguchi, H., Ueda, S. & Kodani, M.
Time-controlled explosion systems and processes for preparing the
same. (1989).
13. Dashevsky, A. & Mohamad, A. Development of pulsatile
multiparticulate drug delivery system coated with aqueous
dispersion Aquacoat® ECD. International Journal of
Pharmaceutics 318, 124-131 (2006).
14. Krögel, I. & Bodmeier, R. Evaluation of an enzyme-containing
capsular shaped pulsatile drug delivery system. Pharmaceutical
Research 16, 1424-1429 (1999).
15. Siepmann, F., Siepmann, J., Walther, M., MacRae, R.J. & Bodmeier,
R. Polymer blends for controlled release coatings. Journal of
Controlled Release 125, 1-15 (2008).
16. Siepmann, F., Siepmann, J., Walther, M., MacRae, R.J. & Bodmeier,
R. Blends of aqueous polymer dispersions used for pellet coating:
Importance of the particle size. Journal of Controlled Release 105,
226-239 (2005).
17. Narisawa, S., Nagata, M., Hirakawa, Y., Kobayashi, M. & Yoshino,
H. An organic acid-induced sigmoidal release system for oral
controlled-release preparations. 2. Permeability enhancement of
eudragit RS coating led by the physicochemical interactions with
organic acid. Journal of Pharmaceutical Sciences 85, 184-188
(1996).
18. Pulsatile Drug Delivery Technology With Variable Lag Times.
(Evonik company).
19. Sharma, S. & Pawar, A. Low density multiparticulate system for
pulsatile release of meloxicam. International Journal of
Pharmaceutics 313, 150-158 (2006).
20. Singh, B.N. & Kim, K.H. Floating drug delivery systems: An
approach to oral controlled drug delivery via gastric retention.
Journal of Controlled Release 63, 235-259 (2000).
21. Yoshida, R., Sakai, K., Okano, T. & Sakurai, Y. Pulsatile drug
delivery systems using hydrogels. Advanced Drug Delivery Reviews
11, 85-108 (1993).
22. Mandal, A.S., et al. Drug delivery system based on
chronobiology—A review. Journal of Controlled Release 147,
314-325 (2010).
23. Youan, B.B.C. Chronopharmaceutics: Gimmick or clinically
relevant approach to drug delivery? Journal of Controlled Release
98, 337-353 (2004).
24. Shi, S. & Klotz, U. Proton pump inhibitors: An update of their
clinical use and pharmacokinetics. European Journal of Clinical
Pharmacology 64, 935-951 (2008).
25. Robinson, M. Review article: The pharmacodynamics and
pharmacokinetics of proton pump inhibitors - Overview and clinical
implications. Alimentary Pharmacology and Therapeutics,
Supplement 20, 1-10 (2004).
26. Satya V. N. Raju, K.P. Preparation of Optically Pure Esomeprazole
and Its Related Salt. Organic Process Research & Development 10,
33-35 (2006).
27. Lou, H.-Y., Chang, C.-C., Sheu, M.-T., Chen, Y.-C. & Ho, H.-O.
Optimal dose regimens of esomeprazole for gastric acid suppression
with minimal influence of the CYP2C19 polymorphism. European
Journal of Clinical Pharmacology 65, 55-64 (2008).
28. Dukic-Ott, A., Thommes, M., Remon, J.P., Kleinebudde, P. &
Vervaet, C. Production of pellets via extrusion-spheronisation
without the incorporation of microcrystalline cellulose: A critical
review. European Journal of Pharmaceutics and Biopharmaceutics
71, 38-46 (2009).
29. Glatt. http://www.glatt.com/cm/.
30. 林山陽. 膜衣包覆技術. 眾光文化事業有限公司 第六章, 175
(中華民國八十五年七月).
31. Lin, S.Y., Lin, K.H. & Li, M.J. Micronized ethylcellulose used for
designing a directly compressed time-controlled disintegration
tablet. Journal of Controlled Release 70, 321-328 (2001).
32. Maroni, A., Zema, L., Cerea, M. & Sangalli, M.E. Oral pulsatile
drug delivery systems. Expert Opinion on Drug Delivery 2, 855-871
(2005).
33. Morita, T. Filmcoating without or insufficient amount of plasticizer.
(2009).
34. Kao, C.C., Chen, S.C. & Sheu, M.T. Lag time method to delay drug
release to various sites in the gastrointestinal tract. Journal of
Controlled Release 44, 263-270 (1997).
35. Wagner, K.G. & McGinity, J.W. Influence of chloride ion exchange
on the permeability and drug release of Eudragit RS 30 D films.
Journal of Controlled Release 82, 385-397 (2002).
論文全文使用權限
  • 不同意授權瀏覽/列印電子全文服務。


  • 若您有任何疑問,請與我們聯絡!
    臺北醫學大學 圖書館 簡莉婷
    E-mail:etds@tmu.edu.tw
    Tel:(02) 2736-1661 ext.2519
    Fax:(02) 2737-5446